Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of autologous dendritic cell vaccination in high-risk locally advanced colon adenocarcinoma
2010-024118-73Phase 2Terminated
- Sponsor
- Cima Universidad de Navarra
- Start
- Jan 2011
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous dendritic cell vaccine in colon adenocarcinoma, sponsored by Cima Universidad de Navarra. Primary endpoint: Relapse-free interval after treatment. Started Jan 2011; status: terminated.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
colon adenocarcinoma
Beyond the preview
Go deeper on 2010-024118-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024118-73.